An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers

INTRODUCTION: Etrolizumab is a novel, dual-action, anti-β7 integrin antibody in development for patients with moderate to severe ulcerative colitis or Crohn’s disease. Phase 3 studies use a prefilled syringe (PFS) for etrolizumab administration. In parallel, an autoinjector (AI) is being developed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tyrrell, Helen, Ravanello, Renato, Pulley, Jennifer, Tang, Meina Tao, Zhang, Wenhui, Abouhossein, Mariam, Tole, Swati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107167/
https://www.ncbi.nlm.nih.gov/pubmed/33778928
http://dx.doi.org/10.1007/s12325-021-01651-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107167/
https://www.ncbi.nlm.nih.gov/pubmed/33778928
http://dx.doi.org/10.1007/s12325-021-01651-8

Ejemplares similares